i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity, which was presented as both a Video Viewpoint Strategy Session and a podcast, provided significant gains in proficiency amongst the health care professionals who participated....

In May of 2022, i3 Health conducted a survey of 230 oncology nurses at the Oncology Nursing Society (ONS) 47th Annual Congress in Anaheim, California, to assess nurses' familiarity and desire to understand genetic evaluation and counseling and LGBTQIA+ cancer care. Genetic evaluation and counseling are ways for patients to better understand their genome and how their DNA might be able to warn them, and even their family, about their risks to certain cancers and diseases. These types of procedure...

i3 Health is honored to be recognized as a 2022 recipient of the Nursing Continuing Professional Development (NCPD) Premier Award presented by the American Nurses Credentialing Center (ANCC) NCPD Accreditation Program. Awarded annually, the NCPD Premier Award is presented to accredited providers that excel in developing high-quality NCPD-accredited educational activities. Recipients of this prestigious award are exemplary organizations that serve as role models in the field of nursing education....

Rochelle Park, NJ—October 4, 2022 – i3 Health and Oncology Data Advisor™ are happy to announce ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, which will be held on Saturday, November 12, 2022. i3 Health is pleased to partner with the National Breast Cancer Foundation® (NBCF). In honor of Breast Cancer Awareness Month, 20% of the registration fee will be donated to NBCF during October. This one-day virtual conference will feature seven engagin...

i3 Health would like to cordially invite you to our upcoming event, Diagnosis and Evidence-Based Management of T-Cell Lymphoma, a live CME/NCPD-approved webinar. Due to high demand, we are pleased to offer two dates and times for this expert-led discussion: Monday, June 13, 2022, at 3:00 PM EDT, and Friday, June 17, 2022, at 12:00 PM EDT. T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States. The clinical and patho...

Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline knowledge gaps regarding the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with B-cell malignancies. Of the 584 learners who took the pretest and began the activity, 539 saw it through to completion. The learners who completed the act...

At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to receive continuing medical education (CME). Thirty-six individuals completed the survey, of whom 35 (97.2%) were physicians and other prescribers of medication. Results showed that despite the ever-increasing ubiquity of technology in our society, uro...

Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline knowledge gaps in the area of checkpoint inhibitor therapies for advanced cervical cancer. Three hundred and ninety-seven learners took part in the educational activity and completed the pre-activity assessment, and 375 of these finished the activity ...